MAIA Biotechnology (MAIA) Stock Price, News & Analysis

Company Overview

MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer. It is also developing second generation telomere targeting agents. The company was incorporated in 2018 and is headquartered in Chicago, Illinois.

Key Stats

• Today's Range: $1.52 to $1.59
• 50-Day Range: $1.48 to $2.01
• 52-Week Range: $1.40 to $3.74
• Volume: 102,294 shs
• Average Volume: 384,973 shs
• Market Capitalization: $52.12 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

MAIA Biotechnology Stock Analysis - MarketRank™

MAIA Biotechnology scored higher than 31% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for MAIA Biotechnology.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for MAIA Biotechnology are expected to decrease in the coming year, from ($1.30) to ($1.35) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of MAIA Biotechnology is -2.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of MAIA Biotechnology is -2.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

MAIA Biotechnology has a P/B Ratio of 13.17. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.25% of the float of MAIA Biotechnology has been sold short.

Short Interest Ratio / Days to Cover

MAIA Biotechnology has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in MAIA Biotechnology has recently increased by 75.25%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

MAIA Biotechnology does not currently pay a dividend.

Dividend Growth

MAIA Biotechnology does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.25% of the float of MAIA Biotechnology has been sold short.

Short Interest Ratio / Days to Cover

MAIA Biotechnology has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in MAIA Biotechnology has recently increased by 75.25%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.9 / 5
• News Sentiment: 0.98

News Sentiment

MAIA Biotechnology has a news sentiment score of 0.98. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.66 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for MAIA Biotechnology this week, compared to 1 article on an average week.

Search Interest

5 people have searched for MAIA on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.

MarketBeat Follows

7 people have added MAIA Biotechnology to their MarketBeat watchlist in the last 30 days. This is an increase of 133% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, MAIA Biotechnology insiders have bought more of their company's stock than they have sold. Specifically, they have bought $50,000.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

32.32% of the stock of MAIA Biotechnology is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 5.65% of the stock of MAIA Biotechnology is held by institutions.

MAIA Stock Analysis - Frequently Asked Questions

How have MAIA shares performed this year?

MAIA Biotechnology's stock was trading at $2.09 on January 1st, 2025. Since then, MAIA shares have decreased by 24.4% and is now trading at $1.58.

How were MAIA Biotechnology's earnings last quarter?

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) released its quarterly earnings results on Tuesday, November, 12th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.32) by $0.21.

Who are MAIA Biotechnology's major shareholders?

MAIA Biotechnology's top institutional shareholders include Centric Wealth Management (1.89%), Geode Capital Management LLC (0.73%), Jane Street Group LLC (0.09%) and Marshall Wace LLP (0.05%). Insiders that own company stock include Stan Smith, Ngar Yee Louie, Vlad Vitoc, Cristian Luput, Ramiro Guerrero and Joseph F Mcguire.
View institutional ownership trends.

How do I buy shares of MAIA Biotechnology?

Shares of MAIA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of MAIA Biotechnology own?

Based on aggregate information from My MarketBeat watchlists, some other companies that MAIA Biotechnology investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Jabil (JBL), Adobe (ADBE) and AppLovin (APP).

Company Calendar

• Last Earnings: 11/12/2024
• Today: 8/23/2025
• Next Earnings (Estimated): 11/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSEAMERICAN:MAIA
• CIK: 1878313
• Web: www.MAIABiotech.com
• Phone: 312-416-8592
• Fax: N/A
• Employees: 9
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($1.38)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$23.25 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -497.29%
• Return on Assets: -165.42%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.19
• Quick Ratio: 2.19

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.12 per share
• Price / Book: 13.17

Miscellaneous

• Outstanding Shares: 32,990,000
• Free Float: 22,330,000
• Market Cap: $52.12 million
• Optionable: Not Optionable
• Beta: 0.01